Nicholas Investment Partners LP Sells 25,559 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Nicholas Investment Partners LP trimmed its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 23.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 84,147 shares of the biopharmaceutical company's stock after selling 25,559 shares during the quarter. Nicholas Investment Partners LP owned 0.05% of TG Therapeutics worth $2,533,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Quadrant Capital Group LLC grew its stake in TG Therapeutics by 137.1% during the 4th quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock valued at $51,000 after acquiring an additional 975 shares in the last quarter. Blue Trust Inc. grew its holdings in shares of TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after acquiring an additional 371 shares in the last quarter. Smartleaf Asset Management LLC increased its stake in shares of TG Therapeutics by 512.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock worth $60,000 after acquiring an additional 1,594 shares during the last quarter. Jones Financial Companies Lllp raised its holdings in shares of TG Therapeutics by 460.7% during the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock worth $64,000 after acquiring an additional 1,737 shares in the last quarter. Finally, Synergy Asset Management LLC acquired a new stake in TG Therapeutics during the fourth quarter valued at $75,000. Institutional investors and hedge funds own 58.58% of the company's stock.

TG Therapeutics Trading Down 0.7%

Shares of NASDAQ:TGTX traded down $0.25 during mid-day trading on Monday, reaching $34.11. The stock had a trading volume of 584,829 shares, compared to its average volume of 2,993,797. The firm has a market cap of $5.42 billion, a PE ratio of -341.07 and a beta of 2.21. The firm has a 50 day simple moving average of $38.59 and a two-hundred day simple moving average of $34.03. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a twelve month low of $15.16 and a twelve month high of $46.48.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.16). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business had revenue of $120.86 million for the quarter, compared to analyst estimates of $117.07 million. During the same period in the previous year, the business posted ($0.07) EPS. The business's quarterly revenue was up 90.4% compared to the same quarter last year. On average, research analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a research report on Tuesday, March 4th. StockNews.com raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $40.80.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.